Trials / Completed
CompletedNCT00042055
CP-461 for the Treatment of Crohn's Disease
A Phase II Pilot Study of CP-461 in the Treatment of Moderately to Severely Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be monitored throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-461 |
Timeline
- Start date
- 2002-07-01
- Completion
- 2003-09-01
- First posted
- 2002-07-24
- Last updated
- 2011-10-17
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00042055. Inclusion in this directory is not an endorsement.